Finally, we reveal the transcriptomic and proteomic signatures of the Dex-Spi combination treatment that underpin the enhanced myeloma cell killing effects and identify a subset of Dex-Spi-regulated targets that predict survival in the CoMMpass patient cohort. This evidence concerns the gene CHGA and plasma cell myeloma.